Abstract Number: L05 • ACR Convergence 2024
Prolonged Plasma Urate-Lowering After a Single Intravenous Administration of PRX-115, a Novel PEGylated Uricase, in Participants with Elevated Urate Levels
Background/Purpose: PEGylated uricases have already demonstrated therapeutic modality in the treatment of refractory gout patients. PRX-115 is a recombinant homotetrameric uricase enzyme, produced from Candida…Abstract Number: 1878 • ACR Convergence 2024
The Associations Between Gout and Ischemic Colitis Among Hospitalized Patients: A Retrospective Nationwide Analysis
Background/Purpose: Gout is the most common form of inflammatory arthropathy. It occurs due to urate crystal deposition within the joint space, usually in the setting…Abstract Number: 1885 • ACR Convergence 2024
Effect of Physical Activity on Mortality in Rheumatoid Arthritis: A Dose-Response Analysis
Background/Purpose: Patients with Rheumatoid arthritis (RA) tend to perform less physical activity compared to the recommended guidelines. The long-term effects of physical activity on mortality…Abstract Number: 1898 • ACR Convergence 2024
Hyperuricemia Is Associated with Higher Levels of Fasting Plasma Glucose and Insulin Resistance in Non-diabetic Subjects
Background/Purpose: Disorders of glucose metabolism are well-known major contributors to morbidity and mortality. Elevated serum uric acid (SUA), a key precursor of gout attacks, is…Abstract Number: 2005 • ACR Convergence 2024
Impact of Anti-drug Antibodies on the Efficacy of SEL-212 in Patients with Chronic Gout Refractory to Conventional Therapy
Background/Purpose: SEL-212 is a once-monthly, investigational, two-component infusion therapy consisting of pegadricase (SEL-037, a pegylated uricase) and immune-tolerizing nanoparticles containing sirolimus (SEL-110), for the treatment…Abstract Number: 2008 • ACR Convergence 2024
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Dose of ABP-671 in Participants with Chronic Kidney Disease (CKD)
Background/Purpose: In this open-label Phase 1 study, 22 participants were enrolled in 3 cohorts, 10 participants with normal kidney function (eGFR ≥90 ml/min/1.73m2 and no…Abstract Number: 2012 • ACR Convergence 2024
Safety, Tolerability and Efficacy of Pegloticase Administered with a Shorter Infusion Duration in Subjects with Uncontrolled Gout Receiving Methotrexate: Primary Findings of the AGILE Open-label Trial
Background/Purpose: Pegloticase, infused every 2 weeks over ≥2 hrs, lowers serum urate (SU) in patients with refractory gout. Decreasing infusion time is expected to improve…Abstract Number: 2013 • ACR Convergence 2024
Elevated Serum Allantoin and Allantoin/uric Acid Ratio as Indicators of Oxidative Stress in Severe Gout and Cardiovascular Comorbidities
Background/Purpose: Uric acid (UA) can be non-enzymatically oxidized into allantoin and other products by reactive oxygen species under conditions of increased oxidative stress. Consequently, allantoin…Abstract Number: 0265 • ACR Convergence 2024
Performance of Two Gout Remission Definitions in a Two-Year Randomized Controlled Trial of Nurse-led Care
Background/Purpose: To compare the performance of the 2016 preliminary gout remission definition and a simplified gout remission definition in a clinical trial of nurse-led gout…Abstract Number: 2014 • ACR Convergence 2024
Effect of a Whole Food Plant-Based Diet in Patients with Gout: A Pilot Randomized Controlled Trial
Background/Purpose: An unhealthy diet is an important modifiable risk factor for hyperuricemia and gout and is also associated with obesity and metabolic syndrome (MetS), known…Abstract Number: 0266 • ACR Convergence 2024
Analysis of Gout Remission Definitions in a Randomised Controlled Trial of Colchicine Prophylaxis for People with Gout Initiating Allopurinol
Background/Purpose: To investigate the effect of colchicine prophylaxis on gout remission when commencing urate lowering therapy (ULT), and illness perceptions of people in remission, using…Abstract Number: 2018 • ACR Convergence 2024
Non-adherence to Urate Lowering Therapy in Gout After 5 Years Is Related to Poor Outcomes – Results from the NOR-Gout Study
Background/Purpose: People with gout need to adhere to medication over time to achieve good outcomes. We assessed self-reported adherence to medication with urate lowering therapy…Abstract Number: 0275 • ACR Convergence 2024
Targeting IRAK4 in Monosodium Urate Crystals Induced Inflammation
Background/Purpose: Gout, the leading cause of inflammatory arthritis, is becoming increasingly prevalent worldwide, affecting both developed and developing countries. This condition results from the deposition…Abstract Number: 2019 • ACR Convergence 2024
Safety and Efficacy of SEL-212 in the US and ex-US Subgroups: Results from the Phase 3 DISSOLVE Studies
Background/Purpose: The DISSOLVE Phase 3 study program investigated the efficacy and safety of SEL-212, a novel, once-monthly, two-component infusion therapy consisting of pegadricase (SEL-037, a…Abstract Number: 0279 • ACR Convergence 2024
Macrophage Intracellular Fates of Monosodium Urate and Calcium Pyrophosphate Crystals: Phagocytosis, Exchanged/expulsion and Dissolution of Crystals
Background/Purpose: Gout, due to the presence of monosodium urate crystals (MSU) and calcium pyrophosphate (CPP) crystal deposition disease are both responsible for recurrent inflammation flares.…
- 1
- 2
- 3
- …
- 8
- Next Page »